Clinical Pharmacology & Therapeutics · 2014 · 58 citations · 5 references
MedicinePharmacokineticsPharmacologyBiochemical PharmacologyClinical PharmacologyDrug InteractionsCytochrome P450 EnzymesCytochrome P450 InteractionsCytochrome P450-mediated MetabolismDrug Safety MonitoringClinical Pharmacology EvidenceClinical Pharmacology ReviewCyp450-mediated InteractionsCytochrome P450 Enzyme InhibitionCytochrome P450 InhibitionRegulatory Standards
High-dose ketoconazole (400 mg q.d. for ≥5 days) has been the gold-standard strong cytochrome P450 3A (CYP3A) inhibitor in drug development drug-drug interaction (DDI) studies. In 2013, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) advised against using this ketoconazole regimen following review of clinical safety reports. We systematically evaluated 19 strong CYP3A inhibitors from regulatory guidances and a literature database to identify itraconazole (200 mg b.i.d. on day 1, q.d. on days 2-6) and clarithromycin (500 mg b.i.d. for 7 days) as acceptable ketoconazole alternatives.
5